Tramadol, buy tramadol, antibiotics, Weight Loss drugs, weight loss herbs, weight loss herbal formula, weight loss, hair loss, hair growth, baldness, Rx Online, pharmaceuticals, DHEA, Lutein, Prescription, Prescription drug, prescription medications, alopecia, Propecia.

DreamPharm Products:

Research Resources:

Alopecia, hair loss abstracts ||

Dermatol Surg. 2002 Sep;28(9):808-16.
An evaluation system to enhance patient selection for alopecia-reducing surgery.

Brandy DA.

Department of Dermatology, University of Pittsburgh Medical Center, Pennsylvania, USA.

BACKGROUND: The author presents an evaluation system that helps optimize the chances of achieving good results with alopecia-reducing procedures. OBJECTIVE: To help hair restoration surgeons select patients properly for alopecia-reducing procedures. METHODS: Twenty criteria are scrutinized by the hair restoration surgeon during the initial consultation and given a score of one to five. The scores are added together and divided by 20. A patient with a score greater than four is considered a good candidate for alopecia reduction in most cases. RESULTS: This evaluation method has significantly decreased the number of patients undergoing alopecia-reducing procedures while helping the author achieve consistently good results. CONCLUSION: An evaluation system is presented that helps determine who is a good candidate for alopecia reduction and who is a poor candidate. This selection technique has helped the author achieve more consistently good results by eliminating poor and borderline candidates.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12269874&dopt=Abstract

Toxicology. 2002 Oct 15;179(3):183-96.
A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats.

Teo S, Stirling D, Thomas S, Hoberman A, Kiorpes A, Khetani V.

Pharmacokinetics and Toxicology, Celgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USA. steelgene.com

D-methylphenidate is an enantiomer of D,L-methylphenidate and was developed as an improved treatment for attention deficit hyperactivity disorder in children. The current study was performed to determine and compare the toxicity of 2-50 mg/kg per day D-MPH and 100 mg/kg per day D,L-MPH for 90 days in rats with the top D-MPH dose being equimolar to 100 mg/kg D,L-MPH. The top D-MPH and D,L-MPH doses were at least 67 times that of the human dose and produced systemic exposures that were over 10 times higher than those typically achieved in children. During the course of the study, one male each from the 50 mg/kg per day and D,L-MPH groups and one female from the 50 mg/kg group died. Incidences of material around nose/eyes, scabbing, foot swelling, alopecia and abrasions were evident at 50 mg/kg per day D-MPH and 100 mg/kg per day D,L-MPH doses. Body weight and its changes decreased in a dose-dependent manner for D-MPH males. There were significant changes in some clinical chemistry measurements at the terminal bleed in the high dose groups of both sexes although most of these changes were resolved by the recovery bleed. Differences in absolute and relative body and certain organ weights for high dose D-MPH and D,L-MPH groups were seen at terminal necropsy with the differences no longer present after the recovery period. No abnormal or gross histopathological changes were associated with any of these organ weight changes reported for the terminal and recovery periods. Based on body weight changes, the no observed adverse effect level for D-MPH in rats was 20 mg/kg. Overall, the toxicity profile observed in rats with 50 mg/kg per day D-MPH was comparable to that of an equimolar dose of D,L-MPH (100 mg/kg per day) when given repeatedly for 90 days using a twice a day dosing regimen.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12270592&dopt=Abstract

J Am Acad Dermatol. 2002 Oct;47(4):519-23.
Atrichia with papular lesions resulting from compound heterozygous mutations in the hairless gene: A lesson for differential diagnosis of alopecia universalis.

Henn W, Zlotogorski A, Lam H, Martinez-Mir A, Zaun H, Christiano AM.

Institute of Human Genetics, Saarland University, Homburg/Saar, Germany.

BACKGROUND: Atrichia with papular lesions (APL) is a rare, autosomal recessive form of total alopecia in which mutations in the hairless (HR) gene have been shown to underlie the phenotype. OBJECTIVE: We suspect that APL is actually much more common than previously believed. We sought to investigate whether APL might also be found among patients in small families, particularly those giving a history of (1) normal hair at birth, which was shed and never regrew, and (2) "alopecia universalis" that is recalcitrant to any treatment. METHODS: We identified a small family of German origin in which 2 of 4 siblings were affected and gave this clinical history. Direct sequence analysis of the HR gene in the nuclear family was performed. RESULTS: Mutation analysis revealed distinct mutations on each allele of the HR gene. This is the first demonstration of compound heterozygous mutations underlying APL. CONCLUSION: These findings support the hypothesis that APL can exist in small nonconsanguineous families and may be masquerading clinically as alopecia universalis. Accurate discrimination between APL and alopecia universalis should prevent unnecessary treatment of patients affected with APL.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12271294&dopt=Abstract

Hair growth is a sophisticated biological process, which is still not thoroughly understood. A multitude of therapeutic measures, including drugs, surgery, and suppelements have been made available, and used. However, due to the diversity of the problems underlying hair loss, there is no single solution for all hair loss cases. Most of chemical drugs and hair transplantation surgeries are not free from varying degrees of undesirable side effects on health.

We only know by anecdotal observations. There has been no clinical trials nor placebo controlled statistical analysis on the efficacy of Hair Million on hair loss and hair growth. For the clinically tested, FDA approved prescription medication, check Propecia.

DHEA has been suggested to provide numerous potential benefits. DHEA (or dehydroepiandrosterone) is converted into androgens (male hormones) or estrogens (female hormones) in the cells.

Herbs and Pharmaceuticals Online|| Best Realtor in Glendale, California: Residential Home and Commercial Property || Related Web pages || Key Links || Buy DHEA Online ||